- Home
- ONIT vs ORKA Comparison
ONIT vs ORKA Comparison
Compare ONIT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONIT
- ORKA
- Stock Information
- Founded
- ONIT 1988
- ORKA 2004
- Country
- ONIT United States
- ORKA United States
- Employees
- ONIT N/A
- ORKA N/A
- Industry
- ONIT
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ONIT
- ORKA Health Care
- Exchange
- ONIT NYSE
- ORKA Nasdaq
- Market Cap
- ONIT 308.3M
- ORKA 354.2M
- IPO Year
- ONIT 1996
- ORKA N/A
- Fundamental
- Price
- ONIT $38.00
- ORKA $11.74
- Analyst Decision
- ONIT Strong Buy
- ORKA Strong Buy
- Analyst Count
- ONIT 2
- ORKA 8
- Target Price
- ONIT $52.50
- ORKA $39.71
- AVG Volume (30 Days)
- ONIT 39.5K
- ORKA 164.6K
- Earning Date
- ONIT 07-31-2025
- ORKA 08-15-2025
- Dividend Yield
- ONIT N/A
- ORKA N/A
- EPS Growth
- ONIT 248.50
- ORKA N/A
- EPS
- ONIT 2.98
- ORKA N/A
- Revenue
- ONIT $986,700,000.00
- ORKA N/A
- Revenue This Year
- ONIT $7.68
- ORKA N/A
- Revenue Next Year
- ONIT $9.23
- ORKA N/A
- P/E Ratio
- ONIT $12.56
- ORKA N/A
- Revenue Growth
- ONIT N/A
- ORKA N/A
- 52 Week Low
- ONIT $22.40
- ORKA $5.49
- 52 Week High
- ONIT $41.27
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- ONIT 51.50
- ORKA N/A
- Support Level
- ONIT $36.10
- ORKA N/A
- Resistance Level
- ONIT $38.00
- ORKA N/A
- Average True Range (ATR)
- ONIT 1.25
- ORKA 0.00
- MACD
- ONIT -0.20
- ORKA 0.00
- Stochastic Oscillator
- ONIT 34.30
- ORKA 0.00
About ONIT ONITY GROUP INC
Onity Group Inc is a non-bank mortgage servicer and originator providing solutions through its brands, PHH Mortgage and Liberty Reverse Mortgage. PHH Mortgage is one of the servicers in the country, focused on delivering a variety of servicing and lending programs. Liberty is one of the nation's reverse mortgage lenders dedicated to education and providing loans that help customers meet their personal and financial needs.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.